Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the ...

Global Non Small-Cell Lung Cancer Market, by Type The non-small cell lung cancer market grow at a CAGR of around 9.3% from 2021-2031.

When small-cell lung cancer (SCLC) has spread to distant parts of the body, it’s classified as extensive-stage, which applies ...

Highlights from ASCO 2025 in early-stage NSCLC include updates on CheckMate 816 on neoadjuvant nivolumab, NeoADAURA on osimertinib, and data on low-dose CT screening, presented by Dr Jonathan Goldman.

Lung cancer is the second most frequent cancer worldwide, and it accounts for 18% of all cancer-related deaths. Most cases of ...

The FDA approved taletrectinib for ROS1-positive NSCLC. The agent shows efficacy for both new and pretreated cases, including ...

The U.S. FDA has approved treatment with Ibtrozi for patients with locally advanced or metastatic ROS1-positive non-small ...

The study is the first, to the researchers’ knowledge, to evaluate both survival and cost metrics across non-small cell lung ...

Vaping might be safer than cigarette smoking, but they carry their own health risks. A New Jersey man’s electronic cigarette ...

Approval was based on results from the Phase II TRUST-I and TRUST-II trials, which demonstrated confirmed overall response ...

Compared with chemotherapy alone, neoadjuvant nivolumab plus chemotherapy extends overall survival in patients with ...

Amgen's Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease had worsened after an initial round of chemo, according to interim data ...